Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Combined With GDP in Stage I/II ENKTL
NCT02276248Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2010
- Primary completion
- Dec 2016
- Modality
- Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, Cisplatin micelle injection (HA132) and dexamethasone in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 2 years. Started Jun 2010; status: completed.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)dexamethasone
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02276248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02276248.